SCHEMBL4208288

SCHEMBL4208288

CCNCc1nc2c(sc3ccc(Cl)cc32)c(=O)[nH]1

nearest known ligand 0.79

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 19/20 0.79
PIM2 Q9P1W9 13/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4207424 0.91 PIM1 (0.76) PIM1PIM2
SCHEMBL4213453 0.88 PIM1 (1.00) PIM1PIM2
SCHEMBL4212353 0.88 PIM1 (0.72) PIM1PIM2
SCHEMBL4199841 0.88 PIM1 (0.74) PIM1PIM2
SCHEMBL4206445 0.86 PIM1 (0.72) PIM1PIM2
SCHEMBL4214534 0.85 PIM1 (0.78) PIM1PIM2
SCHEMBL4213445 0.82 PIM1 (1.00) PIM1PIM2
SCHEMBL4218595 0.81 PIM1 (1.00) PIM1PIM2
SCHEMBL4204980 0.81 PIM1 (1.00) PIM1PIM2
SCHEMBL4210348 0.81 PIM1 (1.00) PIM1PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030196-A1 PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS ABBOTT LABORATORIES (US) 2009-01-29 US claimed
US-7579088-B2 surface treatment by oxidize the surfaces which has hydrophobic character converted to hydrophilic character; applying a water-soluble, dispersible polyphenol resin as protective coatings; increasing paint, ink, and adhesive adhesion; cost effective to prevent defects appear on automobile paint finish HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) 2009-08-25 US disclosed
US-20090030196-A1 PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS ABBOTT LABORATORIES (US) 2009-01-29 US disclosed
US-20060121284-A1 Increasing and maintaining the hydrophilic nature of an oxidized plastic surface HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) 2006-06-08 US disclosed
EP-0319017-B1 Treatment and after-treatment of metal with carbohydrate-modified polyphenol compounds HENKEL CORP (US) 1994-04-13 EP disclosed
US-5068299-A Monomers for polymers containing vinylphenols for protective coatings or decoration HENKEL CORPORATION (US) 1991-11-26 US disclosed
US-4963596-A WATER-SOLUBLE, DISPERSABLE MANNICH DERIVATIVES; CURING TO FILMS AND PROTECTIVE COATINGS; ADHESION, CORROSION RESISTANCE HENKEL CORPORATION (US) 1990-10-16 US disclosed
EP-0319017-A2 Treatment and after-treatment of metal with carbohydrate-modified polyphenol compounds HENKEL CORPORATION (a Delaware corp.) (US) 1989-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030196-A1 PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS PIM1, PIM3, PIM2 PIM1 1/4885PIM2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.